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No-reflow phenomenon, defined as inadequate perfusion of myocardium without evident
artery obstruction, occurs at a high incidence after coronary revascularization. The
mechanisms underlying no-reflow is only partially understood. It is commonly caused
by the swelling of endothelial cells, neutrophil accumulation, and vasoconstriction, which
are all related to acute inflammation. Persistent no-reflow can lead to hospitalization and
mortality. However, an effective preventive intervention has not yet been established.
We have previously found that paeonol, an active extraction from the root of Paeonia
suffruticosa, can benefit the heart function by inhibiting tissue damage after ischemia,
reducing inflammation, and inducing vasodilatation. To further investigate the potential
cardioprotective action of paeonol on no-reflow, healthy male Wistar rats were
randomly divided into four groups: sham, ischemia-reperfusion (I/R) injury (left anterior
descending coronary artery was ligated for 4 h followed by reperfusion for 8 h), and
I/R injury pretreated with paeonol at two different doses. Real-time myocardial contrast
echocardiography was used to monitor regional blood perfusion and cardiac functions.
Our data indicated that paeonol treatment significantly reduces myocardial infarct area
and no-reflow area (n = 8; p < 0.05). Regional myocardial perfusion (A·β) and
cardiac functions such as ejection fraction, stroke volume, and fractional shortening were
elevated by paeonol (n = 8; p < 0.05). Paeonol also lowered the serum levels of lactate
dehydrogenase, creatine kinase, cardiac troponin T, and C-reactive protein, as indices
of myocardial injury. Paeonol exerts beneficial effects on attenuating I/R-associated
no-reflow injuries, and may be considered as a potential preventive treatment for cardiac
diseases or post-coronary revascularization in which no-reflow often occurs.
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INTRODUCTION
Ischemic heart disease is a major cause of morbidity and mortality worldwide (Zuo et al., 2009,
2013; Zhu and Zuo, 2013; Sivaraman and Yellon, 2014). Coronary revascularization, including
thrombolysis, percutaneous coronary intervention (PCI), and bypass grafting, is recognized as
the most effective therapeutic strategy for coronary artery diseases (Niccoli et al., 2009; Serruys
et al., 2009). However, a subset of patients continues to suffer from severe myocardial ischemia
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caused by factors such as myocardial interstitial edema,
microvascular spasm, endothelial cell injury/swelling, neutrophil
accumulation, micro-thromboembolism, and vasoconstriction
related to acute inflammation (Rezkalla and Kloner, 2002; Kaul,
2014; Shao et al., 2014). The persistence of these symptoms,
termed no-reflow phenomena, can cause insufficient regional
blood perfusion, left ventricular (LV) dysfunction, and even
cardiac death (Kawano et al., 2005; Chan et al., 2012; Zeng et al.,
2012). Several attempts have been made to resolve no-reflow
phenomenon with novel interventions associated with Western
medicine, yet no ideal strategy has been established (Ramjane
et al., 2008; Salinas et al., 2012).
Approaches that use traditional Chinese medicinal plants and
their active ingredients, such as Tongxinluo capsule, have been
emerging due to their multi-targeted pharmacological effects
during no-reflow treatment (Wu et al., 2006; Liu et al., 2011).
Other Chinese medicines, such as paeonol, a main constituent
extracted from the root of Paeonia suffruticosa, is regarded as
a traditional Chinese herb that belongs to the Ranunculaceae
family. Studies have observed that paeonol exhibits a wide
range of biological effects, including anti-inflammatory, immune
regulatory, anti-tumor, and anti-oxidative effects (Sun et al.,
2008; Jin et al., 2016). Our previous studies on rat models
have demonstrated that paeonol is therapeutically beneficial
for myocardial infarction by inhibiting tissue damage after
ischemia and inducing vasodilatation in the mesenteric artery
in vivo (Li Y.K. et al., 2010; Zhang et al., 2013). Other
studies showed that paeonol can reduce myocardial damage
by preventing apoptosis in vivo (Nizamutdinova et al., 2008).
However, our understanding of paeonol as a cardioprotective
agent against myocardial ischemia/reperfusion (I/R)-associated
no-reflow phenomenon, is still largely unknown. Therefore,
the current study particularly aims to investigate the effect
of paeonol on no-reflow and regional blood perfusion during
myocardial I/R in rat models. We hypothesize that paeonol exerts
cardioprotective effects by attenuating I/R-associated no-reflow
injuries and thereforemay be considered as a potential preventive
treatment for cardiac diseases or post-coronary revascularization
when no-reflow occurs.
MATERIALS AND METHODS
Experimental Animals and Reagents
Healthy male Wistar rats (180–220 g, average age of 8 week) were
procured from Beijing Si Beifu Laboratory Animal Technology
Co., Ltd. All animal experiments were performed in accordance
with the standards established by the Institutional Animal Care
and Use Committee of Institute of Basic Medical Sciences
of Xiyuan Hospital, and were approved by the Beijing Local
Ethics Review Committee, Beijing University Laboratory Animal
Center (Animal Permit #: SCXK Beijing 2011-0004). The rats
were randomly divided into four groups: (1) sham group,
thoracotomy without left anterior descending coronary artery
(LAD) occlusion or paeonol pretreatment; (2) I/R group, LAD
occlusion (ischemia) for 4 h followed by reperfusion for 8 h;
(3) Paeonol (100mg/kg) + I/R group, oral administration of
100mg/kg paeonol (1mL/kg) for 7 days using a intragastric tube
prior to I/R procedure; (4) Paeonol (200mg/kg)+ I/R group, oral
administration of 200mg/kg paeonol (1mL/kg) for 7 days using
a intragastric tube prior to I/R procedure. In addition, rats in
the sham and I/R groups received a dosage of dimethyl sulfoxide
(DMSO, Beijing Solarbio Science & Technology Co., Ltd., China)
equal to that with which the paeonol was dissolved in for the
other two groups. DMSO was also administered intragastrically
for 7 consecutive days. A minimum of eight rats were assigned
to each group (Zhang et al., 2014). An ischemia group without
reperfusion is not included since our present study mainly
focuses on the effect of paeonol on the cardiac injuries after
reperfusion, which is closely related to the real-world situation
of no-reflow after coronary revascularization. However, future
studies may include a group subjected only to 4 h of ischemia to
differentiate, in terms of damage to the cardiac function, which
was due to the ischemia and which was due to the no-reflow.
Previous literature reported a dose-dependent (30, 50,
100mg/kg) effect of paeonol in reducing inflammation (Chou,
2003). In our myocardial I/R models, 100mg/kg paeonol was
used as low-dose and 200mg/kg as high-dose to ensure a range
of dosage effectiveness. In addition, to our best knowledge, the
duration of drug action for paeonol has not yet been fully
investigated. Taken into account of this, we designed a 7-day
administration period of pretreatment to ensure a sufficient time
for the onset of paeonol. Future studies will focus on the drug
action as well as the dosage effectiveness of paeonol.
Paeonol (purity > 95%) was obtained from Ningbo Dekang
Biologic Product Co., Ltd. (Ningbo, China). Nitro-blue
tetrazolium chloride (NBT) and chloral hydrate were purchased
from Sinopharm Chemical Reagent Co., Ltd. (Beijing, China).
Thioflavin S was purchased from Sigma (St. Louis, MO, USA).
Lactate dehydrogenase (LDH), creatine kinase (CK), cardiac
troponin T (cTnT), and C-reactive protein (CRP) assay kits
were purchased from BioSino Bio-technology and Science
Inc. (Beijing, China). All of the chemicals were dissolved in
physiological saline, except for paeonol, which was dissolved in
DMSO.
Establishment of Myocardial I/R Rat Model
The myocardial I/R model was established previously by Michael
et al. (1995). Briefly, rats were anesthetized via an intraperitoneal
(IP) injection of 3.5% chloral hydrate (1mL/kg) and placed
in a supine position with all paws secured on the operating
table. The left thorax was opened to expose the heart. The
LAD coronary artery was ligated and the chest was closed by
a hemostat for 4 consecutive hours until the reperfusion took
place (Zhang et al., 2014). Although in rodent heart, 30–60min
ischemia is normally sufficient to induce myocardial infarction,
ischemia for 4 h in our setting would lead to a more severe
risk region in order to fully evaluate the therapeutic efficacy
of paeonol during no-reflow, as described previously (Zhang
et al., 2014). Compared tomodels with relatively shorter ischemia
periods, no-reflow area and perfusion area were more clearly
identified in our unique 4 h ischemic model, and the heart
remained viable after this prolonged ischemia caused by LAD
ligation since other coronary arteries were still able to partially
support the blood flow to the left ventricle (Zhang et al., 2014).
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Following the removal of LAD ligation during another chest
opening for reperfusion, the chest was re-sutured and the analysis
was performed 8 h later from the start of reperfusion. In the
sham group, the rat underwent the same chest surgery in the
absence of LAD ligation. The body temperature of the rats
was maintained at all time. The chest opening time during
LAD occlusion and ligation removal was kept at minimum by
experienced surgeons. Successful induction of acute myocardial
I/R model was confirmed by visual inspection of color alteration
in the LV and ST segment-characterized electrocardiogram.
Cardiac Function by Echocardiography
Following 8 h of reperfusion, rats were adequately sedated by 3%
isoflurane (inhaled). Ultrasound gel was placed on the precordial
region of the shaved chest wall, and ultrasound bio-microscopy
(Vevo 770, Visual-Sonics Inc., Toronto, ON, Canada) with a
17.5-MHz transducer was used to visualize the left ventricle.
The LV wall thickness, chamber diameter, and pressure were
measured from the two-dimensional directed images of the
LV (M-mode; short axis below papillary muscle), as previously
described (Samuel et al., 2008). LV function was assessed by
measuring LV end-systolic and end-diastolic volumes, ejection
fraction (EF), stroke volume (SV), and fractional shortening (FS).
All measurements were recorded from at least three consecutive
cardiac cycles and the mean values were reported.
Myocardial Contrast Echocardiography
(MCE) Analysis
Real-time MCE was used to capture MCE sequences during
cardiac cycles and quantitatively analyze the extent of myocardial
blood flow. Regions of interest (ROIs) were positioned at the
anterior wall of LV to measure the non-perfused areas in
our models. Constant infusion of microbubble contrast agent
(0.8ml of 11.8mg/ml per mouse) was performed via tail vein
injection. The total imaging acquisition lasted for ∼12.5 s. The
signal intensity increased immediately following the injection of
contrast agents. The displayed pattern of the curve included an
ascending slope followed by a plateau, indicating an increase
followed by stabilization of the detectable intensity from contrast
agents. The time-dependent perfusion in the heart can be
described with a mathematical model, which can be solved using
nonlinear regression analysis. The exponential curve of time
versus intensity was then graphed based on previous studies
(Raher et al., 2007; Sun et al., 2011).
Signal variation is modeled as y = A (1 − eβt), where y
is the contrast agent replenishment data at any given time. A
(plateau intensity) and β (rate constant of signal intensity rise)
represent microvascular cross-sectional area and blood velocity,
respectively. These values are automatically generated by MCE
software. On the other hand, the calculated product A·β provides
an estimation of myocardial blood flow (Wei et al., 1998; Raher
et al., 2007).
Measurement of Serum Parameters
After the completion of cardiac function assessment and MCE
analysis, thioflavin S (6%, 1mL/kg) was injected into the femoral
vein of all rats for the subsequent examination of the infarct
area. Blood was immediately collected from the abdominal aorta
and centrifuged at 1050 × g for 2 × 10min. The serum was
analyzed using assay kits to detect the activities of LDH, CK,
cTnT, and CRP. All procedures were performed according to
FIGURE 1 | Effects of paeonol on myocardial infarct area in
ischemia/reperfusion (I/R) rats. (A) Representative images of the infarct
area for all four groups [Sham, I/R, paeonol (100mg/kg) + I/R, paeonol
(200mg/kg) + I/R], with the arrows showing nitro-blue tetrazolium chloride
(NBT)-negative infarct areas. (B) The percentage of the infarct area to the
ventricle size (AI/V) and to the whole heart section (AI/WH) in the three groups.
I/R group (n = 9), paeonol (100mg/kg) + I/R group (n = 8), paeonol
(200mg/kg) + I/R group (n = 8). The data are expressed as mean ± SE.
#p < 0.01, compared with I/R group of the ventricle size. †p < 0.05,
compared with I/R group of the whole heart.
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the manufacturer’s protocol (Goldberg et al., 2006; Xia et al.,
2014).
Myocardial Staining for No-Reflow and
Infarct Area Evaluation
Rats were sacrificed immediately by removing the whole heart.
The heart was transected into five even slices parallel to the
atrioventricular groove. The slices were photographed under
ultraviolet light (UV, 365 nm) to identify the region of no-reflow.
By thioflavin S staining, areas that were perfused with blood
were fluorescent, whereas areas that were not perfused appeared
dark (Shao et al., 2013). The slices were then incubated in 0.2%
NBT for 3min in room temperature, immersed in formalin, and
photographed again. Infarct area was unstained by NBT and the
non-infarct area was stained dark brown (Kloner et al., 1974). The
no-reflow and infarct areas were measured by a multimedia color
pathological image analytical system (MPIAS-500, Beijing Kong
Hai Science and Technology Development Co., Ltd., China).
Data of no-reflow area were determined as the percentage of the
no-reflow area to the ventricle size (AN/V) or the no-reflow area
to the whole heart section (AN/WH). Data of infarct area were
determined as the percentage of the infarct area to the ventricle
size (AI/V) or the infarct area to the whole heart section (AI/WH;
Shao et al., 2013).
Statistical Analysis
Data were analyzed using SPSS 17.0 software (SPSS Inc., Chicago,
IL, USA) and the values are expressed as mean ± standard
error (SE). A normality test was performed on all presented
data and the differences between each group were assessed by
nonparametric Mann-Whitney test. The results were considered
significant at p < 0.05.
RESULTS
Effects of Paeonol on Myocardial Infarct
Area
Initial in vivo experiment of paeonol was performed in rat models
of myocardial I/R induced by LAD ligation. Different doses of
paeonol (100 and 200mg/kg) were used during the pretreatment
of two experimental groups.Myocardial injury was evident by the
quantitative measurement of acute myocardial infarct sizes. The
200mg/kg paeonol + I/R group [AI/V (%): 18.3 ± 3.1, p < 0.01;
AI/WH (%): 10.8 ± 1.8, p < 0.05] and 100mg/kg paeonol + I/R
group [AI/WH (%): 11.9 ± 2.1, p < 0.05] exhibited significant
reductions in the infarct area compared with the I/R group [AI/V
(%): 34.2 ± 3.2; AI/WH (%): 18.1 ± 1.9] (Figure 1, Datasheet
2). However, the comparison between the 100mg/kg paeonol +
I/R group and the 200mg/kg paeonol + I/R group showed no
significant difference in the infarct area reduction (AI/V, p >
0.05; AI/WH, p > 0.05).
Effects of Paeonol on No-Reflow Area
The 200mg/kg paeonol + I/R group [AN/V (%): 7.6 ± 2.2, p <
0.01] and 100mg/kg paeonol + I/R group [AN/V (%): 9.4 ± 2.8,
p < 0.05] both showed lesser extents of no-reflow area in the
ventricles compared with the I/R group [AN/V (%): 18.2 ± 2.9].
FIGURE 2 | Effects of paeonol on no-reflow area in myocardial
ischemia/reperfusion (I/R) rats. (A) Representative images of the no-reflow
area for all four groups [Sham, I/R, paeonol (100mg/kg) + I/R, paeonol
(200mg/kg) + I/R], with the arrows showing no-reflow areas. (B) The
percentage of the no-reflow area to the ventricle size (AN/V) and to the whole
heart section (AN/WH) in the three groups. I/R group (n = 9), paeonol
(100mg/kg) + I/R group (n = 8), paeonol (200mg/kg) + I/R group (n = 8). The
data are expressed as mean ± SE. *p < 0.05, compared with I/R group of the
ventricle size. †p < 0.05, compared with I/R group of the whole heart.
In particular, the 200mg/kg paeonol + I/R group experienced
markedly alleviated no-reflow in the whole heart [AN/WH (%):
4.6 ± 1.0, p < 0.05] compared with the I/R group [AN/WH (%):
10.0 ± 1.9] (Figure 2, Datasheet 4). Furthermore, no significant
difference in no-reflow area was found between the two dosages
of paeonol (AN/V, p > 0.05; AN/WH, p > 0.05).
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FIGURE 3 | Effect of paeonol on regional myocardial blood flow.
Representative images of regional myocardial blood flow of the four groups.
Sham group (n = 9), I/R group (n = 9), paeonol (100mg/kg) + I/R group
(n = 8), paeonol (200mg/kg) + I/R group (n = 8). The arrows indicate the time
point for the contrast agent injection.
Effects of Paeonol on Regional Myocardial
Blood Flow
The quantitation of paeonol’s effect on the regional myocardial
blood flow was assessed by MCE (Figure 3 and Table 1). The
results showed that β (0.28 ± 0.03 /s, p < 0.05), A (102.21 ±
11.69 dβ, p < 0.01) and A·β (26.76 ± 2.39 dβ/s, p < 0.001) were
significantly decreased in the I/R group compared with the sham
group (0.42 ± 0.05 /s, 193.33 ± 13.34 dβ, 86.32 ± 18.65 dβ/s),
respectively. In the paeonol-pretreated groups, β (200mg/kg
paeonol group: 0.43 ± 0.05 /s, p < 0.05; 100mg/kg paeonol
group: 0.55 ± 0.11 /s, p < 0.01), A (200mg/kg paeonol group:
173.79 ± 15.99 dβ, p < 0.01; 100mg/kg paeonol group: 183.83
± 17.01 dβ, p < 0.01) and A·β (200mg/kg paeonol group: 70.01
± 7.06 dβ/s, p < 0.001; 100mg/kg paeonol group: 87.32 ± 14.82
dβ/s, p < 0.001), were significantly increased as compared to that
in the I/R group (Table 1, Datasheet 3). However, no significant
dose-dependent difference in MCE results was observed between
two doses of paeonol (100mg/kg vs. 200mg/kg; β, p > 0.05; A,
p > 0.05; A·β, p > 0.05).
Effects of Paeonol on Cardiac Function in
Myocardial I/R Rats
We also examined whether paeonol alters cardiac functional
parameters in myocardial I/R rats using echocardiographic
recording (Figure 4). The LV anterior wall systolic and diastolic
thicknesses (LVAW d/s) were significantly improved in the
200mg/kg paeonol + I/R group (n = 8; p < 0.05) and
the 100mg/kg paeonol + I/R group (LVAW d; n = 8;
p < 0.01) compared with that in the I/R group. However,
TABLE 1 | Quantitative MCE analysis of regional myocardial blood flow.
A (dB) β (s−1) A·β (dB/s)
Groups
Sham (n = 9) 193.33±13.34 0.42±0.05 86.32±18.65
I/R (n = 9) 102.21±11.691 0.28±0.03‡ 26.76±2.39§
Paeonol (100mg/kg) +
I/R (n = 8)
183.83±17.01# 0.55±0.11# 87.32±14.82†
Paeonol (200mg/kg) +
I/R (n = 8)
173.79±15.99# 0.43±0.05* 70.01±7.06†
A, plateau; β, rise rate of the signal intensity; A·β, regional myocardial perfusion.
Values are mean ± SE.
*p < 0.05, #p < 0.01,
†
p < 0.001 vs. I/R group.
‡
p < 0.05, ∆p < 0.01,§p < 0.001 vs. sham group.
FIGURE 4 | Effect of paeonol on cardiac function evaluated by
echocardiography. (A) Representative echocardiographic images of the four
groups after the surgical procedure. Each image shown is 1-s duration of the
entire echocardiograph. (B) Percentage of ejection fraction (EF) and fractional
shortening (FS) affected by paeonol. Sham group (n = 9), I/R group (n = 9),
paeonol (100mg/kg) + I/R group (n = 8), paeonol (200mg/kg) + I/R group
(n = 8). *p < 0.05 compared with I/R group. 1p < 0.001 compared with sham
group.
no marked differences in the LV posterior wall diastolic and
systolic thickness (LVPW d/s) were observed. The LV internal
diameter in systole (LVID s) was reduced only in the 200mg/kg
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TABLE 2 | Echocardiographic analysis of cardiac function in four groups.
Sham I/R Paeonol (100mg/kg) + I/R Paeonol (200mg/kg) + I/R
n 9 9 8 8
LVAW d (mm) 1.89± 0.07 1.49±0.08‡ 1.86±0.12# 1.89± 0.10*
LVAW s (mm) 2.75± 0.10 1.63±0.111 1.97±0.10* 2.11± 0.08#
LVPW d (mm) 1.90± 0.08 1.87±0.09 1.86±0.11 2.02± 0.07
LVPW s (mm) 2.67± 0.11 2.21±0.23 2.58±0.20 2.84± 0.28
LVID d (mm) 6.70± 0.15 7.64±0.29† 7.34±0.36 7.03± 0.14
LVID s (mm) 3.91± 0.27 6.30±0.411 5.25±0.50 4.84± 0.19#
LVV d (µl) 236.10± 10.77 316.18±26.06† 253.31±23.84 257.92± 13.69
LVV s (µl) 70.32± 9.71 208.88±30.55‡ 116.07±26.36* 110.55± 10.68#
EF (%) 71.13± 3.25 36.17±5.531 57.73±5.91* 57.09± 2.73*
FS (%) 42.41± 3.17 18.68±3.251 32.44±4.24* 31.92± 2.08*
SV (µl) 165.78± 4.76 107.30±12.891 137.24±5.76 147.37± 7.71*
LVAW d/s, left ventricle anterior wall diastolic and systolic thicknesses; LVPW d/s, left ventricle posterior wall diastolic and systolic thickness; LVID d/s, left ventricle internal diameter in
diastole and systole; LVV d/s, left ventricle volume in diastole and systole; EF, ejection fraction; FS, fractional shortening; SV, stroke volume.
Values are mean ± SE.
*p < 0.05, #p < 0.01 vs. I/R group.
†
p < 0.05,
‡
p < 0.01, ∆p < 0.001 vs. sham group.
paeonol-pretreated + I/R group (n = 8; p < 0.01), and LVID
in diastole (LVID d) in both paeonol-pretreated groups showed
no significant difference when compared to I/R group. The LV
volume in systole (LVV s) was significantly decreased (n = 8;
p < 0.05) in both 200mg/kg paeonol+ I/R group and 100mg/kg
paeonol+ I/R group, whereas LVV in diastole (LVV d) expressed
no marked difference (Table 2). Along with elevated EF and FS
in both paeonol-pretreated groups (n = 8; p < 0.05; Table 2),
these results showed improved cardiac function with paeonol
treatment. Interestingly, greater SV was observed only in the
200mg/kg paeonol + I/R group (n = 8; p < 0.05), yet no
significant difference was seen in the 100mg/kg paeonol + I/R
group (Table 2, Datasheet 1).
Effects of Paeonol on Serum LDH, CK,
cTnT, and CRP Levels in Myocardial I/R
Rats
LDH, CK, cTnT, and CRP concentrations were all elevated in
the I/R group [LDH (U/L): 1128.67 ± 124.80, p < 0.05;
CK (U/L): 686.28 ± 46.25, p < 0.05; cTnT (µg/L): 181.94
± 4.72, p < 0.001; CRP (ng/L): 1570.96 ± 60.31, p <
0.001] compared with the sham group [LDH (U/L): 607.11
± 114.35; CK (U/L): 468.56 ± 50.93; cTnT (µg/L): 24.89 ±
1.16; CRP (ng/L): 1024.18 ± 55.45]. In the paeonol-pretreated
groups, a marked reduction in LDH concentration was observed
in 100mg/kg paeonol + I/R group [LDH (U/L): 730.28 ±
167.25]; yet 200mg/kg paeonol + I/R group [LDH (U/L): 774.00
± 69.97; CK (U/L): 486.99 ± 61.83; cTnT (µg/L): 167.03 ±
2.63; CRP (ng/L): 1396.79 ± 42.88] significantly declined all
four biomarker measurements compared with the I/R group
(n = 9; p < 0.05, Figures 5A–D, Datasheet 5). Moreover, the
comparison between the two paeonol-pretreated groups showed
no significant difference in LDH, CK, cTnT, and CRP levels
(p > 0.05).
DISCUSSION
No-reflow phenomenon emerges when blood fails to reperfuse an
ischemic area after coronary revascularization (Shao et al., 2013).
When no-reflow occurs, pharmacological treatments including
intracoronary verapamil and adenosine, as well as mechanical
therapies (e.g., aspiration thrombectomy) can be used to partially
relieve microvasculature obstruction and improve blood flow
in the heart. However, the development of a more efficient
treatment, especially the prevention of no-reflow, still remains
extremely challenging due to the complexity of this phenomenon
(Ramjane et al., 2008; Berg and Buhari, 2012). As one of the
active compounds in P. suffruticosa, paeonol has been shown to
exert beneficial effects, such as vascular dilation and arrhythmia
improvements (Li Y.J. et al., 2010; Li et al., 2012). Our findings
of the effect of paeonol on regional blood perfusion in the
present study are consistent with the aforementioned reports. In
particular, our results further indicated that pretreatment with
paeonol reduced no-reflow area in conjunction with marked
decreased release of serum CK and LDH, as well as a slight
decline of cTnT and CRP. Our study is the first to show that
paeonol pretreatment has pharmacologically protective effects
on the no-reflow phenomenon. This result, consistent with our
hypothesis, provides evidence that using paeonol may be a
preventive strategy for no-reflow injuries in cardiac diseases or
post-coronary revascularization, warranting pre-clinical testing
in other models.
Myocardial infarction and no-reflow are the major
manifestations of reperfusion injury (Kloner et al., 2012).
Our data showed that paeonol significantly minimized the
no-reflow area. Consequently, the same trend was observed
in the infarct area, indicating that the extent of no-reflow was
likely correlated with the extent of infarction, consistent with
literature (Coggins et al., 2001). Furthermore, we observed
a reduction in the release of LDH, CK, cTnT, and CRP, all
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FIGURE 5 | Effects of paeonol on the levels of serum biomarkers, lactate dehydrogenase (LDH; A), creatine kinase (CK; B), cardiac troponin T (cTnT;
C), and C-reactive protein (CRP; D), in the four groups. Sham group (n = 9), I/R group (n = 9), paeonol (100mg/kg) + I/R group (n = 8), paeonol (200mg/kg) +
I/R group (n = 8). The data are expressed as mean ± SE. *p < 0.05, compared with I/R group; #p < 0.05, ##p < 0.001, compared with sham group.
of which are indicators of potential myocardial injuries in
200mg/kg paeonol-pretreated rat group, although no significant
dose-dependent difference is observed between the two doses of
paeonol. LDH and CK are important markers of cellular necrosis
(Xia et al., 2014). Elevated CK and cTnT levels, which are often
associated with systemic inflammation, have been detected in
angina patients undergoing PCI (Goldberg et al., 2006). Thus,
our results suggested that the paeonol treatment may alleviate
myocardial injury in rat models at molecular levels.
Real-time MCE is a promising echocardiography technology
that is clinically applied for the noninvasive evaluation of
myocardial capillary perfusion in patients (Agati et al., 2004).
Given that myocardial infarctions are closely related to the
insufficient blood supply (Wagner et al., 2002; Thygesen et al.,
2007), we examined regional myocardial blood flow by MCE
in myocardial I/R rats. We found that paeonol significantly
increased the plateau (A), rise rate of the signal intensity (β), and
regional myocardial perfusion (A·β) in both paeonol-pretreated
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groups. These observations showed that paeonol pretreatment
reduced myocardial ischemic damage most likely via a potential
modulation of microvasculature. In the long run, paeonol may
enhance the blood supply of impaired microvessels, thereby
impeding myocardial I/R-associated no-reflow. Based on our
results, LVAW, EF, FS, and SV were dramatically elevated,
whereas LVID s and LVV s were markedly decreased compared
with the groups with no paeonol pretreatment, benefitting
cardiac performance. However, some cardiac functions including
LVID d and LVV d showed no significant difference in the
paeonol-pretreated groups compared to I/R groups, which is
likely due to the use of non-optimal dosage of paeonol and/or
insufficient duration of administration in the present study.
Notably, no marked difference in certain measured parameters
(including infarct area, no-reflow area, regional myocardial
blood flow and cardiac function) was found between the two
doses of paeonol, indicating the importance of evaluating and
determining the dose effectiveness, administration duration, and
onset of paeonol.
The upregulation of Bcl-2 family proteins signals cell
death under I/R stress, but the effect is diminished upon
paeonol treatment (Li et al., 2012). Indeed, the most studied
pharmacological intervention for no-reflow, verapamil, is a
calcium channel blocker that improves coronary blood flow (Berg
and Buhari, 2012). Previous studies have shown that paeonol
induces vasodilatation of the rat mesenteric arteries by regulating
intracellular Ca2+ concentration and improves Ca2+ATPase
activity in the ischemic tissue (Zhang et al., 1997, 2013; Yuan
and Jing, 2011). It is possible that paeonol suppresses both Ca2+
overload and hyper-contracture, thus eliciting beneficial effects
on cardiac function. However, the exact molecular mechanisms
underlying the protective effect of paeonol in no-reflow have
not been fully elucidated. Particularly, Li et al. observed an
enhanced antioxidant defense in the paeonol-treated rat group,
suggesting Nrf2 activation may be involved in the upregulation
of paeonol’s cardioprotective signaling cascades (Li et al., 2012).
Since reactive oxygen species have been shown to play a critical
role in almost all biological systems and pathological conditions,
including I/R injuries, further research could be focused on the
redox mechanism initiated by paeonol (Zuo et al., 2011a,b, 2014,
2015a,b).
We explored the preventive effect of paeonol on no-
reflow injuries, which commonly occurred after coronary
revascularization. Therefore, the administration of paeonol
before any potential cardiac attack or at a daily basis may still
be a feasible real-world prevention. Limitations of this study
may include the fact that the exact molecular mechanisms
of paeonol’s cardioprotective effects associated with multiple
cardiac variables are still not fully understood at the current
stage of the study. Our experiment has not yet fully identified
the optimal dosages for paeonol’s protection to the heart. We
did not find any significance of infarct area, no-reflow area,
and regional myocardial blood flow between the two doses of
paeonol, suggesting the necessity for further experiments to
determine the dose effectiveness and administration strategies
for paeonol. Moreover, since the paeonol treatment does
not have any standard pharmacological treatments in our
analyzed variables, future efforts may be focused on the optimal
dosage effectiveness as well as the duration of drug action of
paeonol.
CONCLUSION
This study has shown the functional cardioprotective properties
of paeonol in vivo rat model. Paeonol minimized the sizes
of myocardial infarct area and no-reflow area, and improved
regional myocardial blood flow and cardiac function. Our results
demonstrate that paeonol may be an alternative drug for clinical
application in the prevention of myocardial I/R-associated no-
reflow and other related cardiac diseases.
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